Utibron Neohaler Drug Interactions
Currently displaying 95 drugs known to have a minor interaction with Utibron Neohaler (glycopyrrolate / indacaterol).
- 22 major drug interactions
- 488 moderate drug interactions
- 95 minor drug interactions
Minor interactions with Utibron Neohaler (glycopyrrolate / indacaterol)
Note: Showing generic names only.
A
B
C
- capmatinib
- chloramphenicol
- ciclesonide
- clotrimazole
- cobicistat
- conivaptan
- corticorelin
- corticotropin
- cortisone
- cosyntropin
- cyclosporine
D
E
F
- fedratinib
- flibanserin
- fludrocortisone
- flunisolide
- fluticasone
- fluvoxamine
- fosamprenavir
- fosaprepitant
- futibatinib
H
I
- idelalisib
- imatinib
- indinavir
- ipratropium nasal
- isavuconazonium
- istradefylline
- itraconazole
- ivacaftor
L
M
N
P
R
S
T
U
V
Utibron Neohaler alcohol/food interactions
There are 4 alcohol/food interactions with Utibron Neohaler (glycopyrrolate / indacaterol).
Utibron Neohaler disease interactions
There are 19 disease interactions with Utibron Neohaler (glycopyrrolate / indacaterol) which include:
- arrhythmias
- autonomic neuropathy
- GI obstruction
- glaucoma
- obstructive uropathy
- tardive dyskinesia
- infectious diarrhea
- myasthenia gravis
- ulcerative colitis
- psychoses
- cardiovascular
- diabetes
- hypokalemia
- seizures
- Down's syndrome
- liver impairment
- renal impairment
- hypertension
- fever
More about Utibron Neohaler (glycopyrrolate / indacaterol)
- Utibron Neohaler consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bronchodilator combinations
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.